{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:55:18Z","timestamp":1761872118673,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.clml.2022.09.009","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T23:39:47Z","timestamp":1665099587000},"page":"49-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical and Radiographic Predictors of Progression and Survival in Relapsed\/Refractory Lymphoma Patients Receiving Anti-CD19 CAR T-cell Therapy"],"prefix":"10.1016","volume":"23","author":[{"given":"Gray","family":"Jodon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7380-1341","authenticated-orcid":false,"given":"Meryl D.","family":"Colton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Abbott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3872-0615","authenticated-orcid":false,"given":"Bradley","family":"Haverkos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3881-7257","authenticated-orcid":false,"given":"Rustain","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manali","family":"Kamdar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.09.009_bib0001","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.09.009_bib0002","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.09.009_bib0003","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2022.09.009_bib0004","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1182\/bloodadvances.2019000151","article-title":"Tisagenlecleucel in relapsed\/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion","volume":"3","author":"Bishop","year":"2019","journal-title":"Blood Adv"},{"issue":"27","key":"10.1016\/j.clml.2022.09.009_bib0005","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large b-cell lymphoma: results from the US lymphoma CAR T consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.09.009_bib0006","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1182\/bloodadvances.2020001837","article-title":"Bridging therapy prior to axicabtagene ciloleucel for relapsed\/refractory large B-cell lymphoma","volume":"4","author":"Pinnix","year":"2020","journal-title":"Blood Adv"},{"issue":"27","key":"10.1016\/j.clml.2022.09.009_bib0007","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity","volume":"38","author":"Jacobson","year":"2020","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clml.2022.09.009_bib0008","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/ajh.25951","article-title":"Use of commercial anti-CD19 CAR T cell therapy for patients with relapsed\/refractory aggressive b cell lymphoma in a European center","volume":"95","author":"Sesques","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2022.09.009_bib0009","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2022.09.009_bib0010","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.bbmt.2019.02.008","article-title":"Role of fluorodeoxyglucose positron emission tomography\/computed tomography in predicting the adverse effects of chimeric antigen receptor t cell therapy in patients with non-hodgkin lymphoma","volume":"25","author":"Wang","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2022.09.009_bib0011","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0167-9473(98)00096-6","article-title":"An application of changepoint methods in studying the effect of age on survival in breast cancer","volume":"30","author":"Contal","year":"1999","journal-title":"Computational Statistics & Data Analysis"},{"key":"10.1016\/j.clml.2022.09.009_bib0012","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3109\/10428194.2013.802784","article-title":"Report on the 4th international workshop on positron emission tomography in lymphoma held in menton, France, 3-5 October 2012","volume":"55","author":"Meignan","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.09.009_bib0013","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1182\/blood-2014-12-616474","article-title":"Utility of baseline 18FDG-PET\/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma","volume":"126","author":"Ceriani","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.09.009_bib0014","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00259-016-3315-7","article-title":"Combination of baseline metabolic tumour volume and early response on PET\/CT improves progression-free survival prediction in DLBCL","volume":"43","author":"Mikhaeel","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clml.2022.09.009_bib0015","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","article-title":"Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies","volume":"34","author":"Meignan","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.09.009_bib0016","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/annonc\/mdw011","article-title":"Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET\/CT in patients with peripheral T-cell lymphoma (PTCL)","volume":"27","author":"Cottereau","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2022.09.009_bib0017","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s00259-014-2822-7","article-title":"Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma","volume":"41","author":"Sasanelli","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clml.2022.09.009_bib0018","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.2967\/jnumed.119.227249","article-title":"Time to prepare for risk adaptation in lymphoma by standardizing measurement of metabolic tumor burden","volume":"60","author":"Barrington","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clml.2022.09.009_bib0019","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20210448","article-title":"Total tumor burden in lymphoma - an evolving strong prognostic parameter","volume":"94","author":"Meignan","year":"2021","journal-title":"Br J Radiol"},{"key":"10.1016\/j.clml.2022.09.009_bib0020","doi-asserted-by":"crossref","first-page":"12590","DOI":"10.1038\/s41598-020-69577-9","article-title":"Comparison of different automatic methods for the delineation of the total metabolic tumor volume in I-II stage Hodgkin Lymphoma","volume":"10","author":"Mart\u00edn-Saladich","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.clml.2022.09.009_bib0021","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large b-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.09.009_bib0022","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2022.09.009_bib0023","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.09.009_bib0024","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/cncr.27855","article-title":"Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma","volume":"119","author":"Kim","year":"2013","journal-title":"Cancer"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022016883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022016883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:40:46Z","timestamp":1761871246000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022016883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S2152265022016883"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.09.009","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and Radiographic Predictors of Progression and Survival in Relapsed\/Refractory Lymphoma Patients Receiving Anti-CD19 CAR T-cell Therapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}